Companion Animals

If there is one field in which Ceva Santé Animale has demonstrated the full extent of its innovation capacities, it is that of companion animals.

A rich source of innovation for the Ceva Group

If there is one field in which Ceva Santé Animale has demonstrated the full extent of its innovation capacities, it is that of companion animals.

Cat and dog behaviour

Through several major innovations, Ceva has opened up the possibility for vets to address behavioural disorders in cats and dogs, an area about which little was known until now and the subject of few clinical studies.

  • 1996: Beginning of a new therapeutic approach: launch of FELIWAY® to treat behavioural disorders in cats
  • 1997: Launch of SELGIAN® (Selegiline) to treat behavioural disorders in dogs
  • 2000: Launch of D.A.P.® providing an innovative approach to the behavioural problems that are specific to the species.

Canine cardiology

Although it benefits from little media attention (compared with flea treatments, for example!), cardiology is a science in which progress is being achieved, extending the lifespan of dogs in parallel with that of their owners.

Why should we just accept the accelerated ageing of our trusty companions when the owner is treated for the same type of pathology?
It is this type of modern sociological approach to the issue that drove the CEVA Group pharmaceutical development teams to propose a range of medicines to treat heart problems in dogs, includingPRILENAL® (enalapril) and, above all, PRILACTONE® (spironolactone), the world’s first veterinary application of a molecule already in use in human medicine.


When we speak of locomotion in companion animals, the key problem is the degenerative joint disease - arthrosis that affects our cats and dogs as they live longer.
For these animals, CEVA has developed specialities that are widely recognised for their efficacy: anti-inflammatory drugs (CARPRODYL®, MELOXIDYL®) or chondroprotectors (FLEXIVET®).
But the best example of locomotion disorders is that of lameness in horses.
It was only in 2001 that a genuine therapeutic solution was finally made available for these extreme disabilities, with the European market launch of TILDREN® (tiludronate), the first veterinary bisphosphonate offering the possibility to treat bone-related lameness in horses.

Other therapeutic fields

Another innovation comes in the field of reproduction: GALASTOP®, a prolactin inhibitor used to treat lactation in pseudopregnancy (“false pregnancies”) in dogs.
Mention should also be made of DIARSANYL® (Montmorillonite), an adjunct treatment for idiopathic diarrhoea in cats and dogs.

From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the Ceva Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Back to top